Literature DB >> 36131028

Butorphanol inhibits angiogenesis and migration of hepatocellular carcinoma and regulates MAPK pathway.

Peilei Guo1, Qiangfu Hu2, Jiandong Wang2, Longzhu Hai2, Xiaohong Nie2, Qingyuan Zhao2.   

Abstract

Butorphanol, a synthetic opioid, exerts analgesic and anti-inflammatory effects against pathogenic diseases. Butorphanol repressed malignant behaviors of tumor cells. In this study, the role of butorphanol in hepatocellular carcinoma was evaluated. Firstly, hepatocellular carcinoma cells were treated with butorphanol. The results showed that butorphanol decreased cell viability of hepatocellular carcinoma cells. Cell proliferation and metastasis of hepatocellular carcinoma cells were inhibited by butorphanol. Secondly, butorphanol suppressed angiogenesis, and reduced phosphorylation levels of p38 and JNK in hepatocellular carcinoma cells. Thirdly, butorphanol reduced in vivo tumor growth of hepatocellular carcinoma in nude mice. Butorphanol reduced tumor micro-vascular density (MVD) and repressed lung metastasis. In conclusion, butorphanol exerted anti-angiogenic and anti-metastatic effects on hepatocellular carcinoma and induced inactivation of MAPKs signaling.
© 2022. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36131028     DOI: 10.1038/s41429-022-00565-z

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   3.424


  2 in total

1.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.

Authors:  Kalpna Gupta; Smita Kshirsagar; Liming Chang; Robert Schwartz; Ping-Y Law; Doug Yee; Robert P Hebbel
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

2.  Effect of ketamine combined with butorphanol on emergence agitation of postoperative patients with gastric cancer.

Authors:  Liang Lin; Shuncui Liu; Zhenyi Chen; Shaoli Lin
Journal:  Ther Clin Risk Manag       Date:  2016-05-04       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.